Given the methods employed, it would be a reasonable estimate that these patients with elevated ALT and four concurrent metabolic co-morbidities have NASH, thus making the estimates of advanced fibrosis and cirrhosis prevalence among this group quite concerning. This evidence concerns the gene GPT and Cirrhosis.